These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 27836119)

  • 61. Five-year clinical outcomes of scanning carbon-ion radiotherapy for prostate cancer.
    Takakusagi Y; Koge H; Kano K; Shima S; Tsuchida K; Mizoguchi N; Yoshida D; Kamada T; Katoh H
    PLoS One; 2024; 19(3):e0290617. PubMed ID: 38457424
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control.
    De Meerleer GO; Fonteyne VH; Vakaet L; Villeirs GM; Denoyette L; Verbaeys A; Lummen N; De Neve WJ
    Radiother Oncol; 2007 Feb; 82(2):160-6. PubMed ID: 17222931
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Five-Year Survival Outcomes After Carbon-Ion Radiotherapy for Operable Stage I NSCLC: A Japanese National Registry Study (J-CROS-LUNG).
    Kubo N; Suefuji H; Nakajima M; Tokumaru S; Okano N; Yoshida D; Suzuki O; Ishikawa H; Satouchi M; Nakayama H; Shimizu K; Shioyama Y
    J Thorac Oncol; 2024 Mar; 19(3):491-499. PubMed ID: 37924974
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cost-effectiveness of carbon ion radiation therapy for locally recurrent rectal cancer.
    Mobaraki A; Ohno T; Yamada S; Sakurai H; Nakano T
    Cancer Sci; 2010 Aug; 101(8):1834-9. PubMed ID: 20500516
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study.
    Ishikawa H; Tsuji H; Kamada T; Yanagi T; Mizoe JE; Kanai T; Morita S; Wakatsuki M; Shimazaki J; Tsujii H;
    Radiother Oncol; 2006 Oct; 81(1):57-64. PubMed ID: 16971008
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
    Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
    Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer.
    Ishikawa H; Tsuji H; Kamada T; Hirasawa N; Yanagi T; Mizoe JE; Akakura K; Suzuki H; Shimazaki J; Tsujii H
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1084-91. PubMed ID: 16979840
    [TBL] [Abstract][Full Text] [Related]  

  • 68. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of carbon ion radiotherapy for primary spinal sarcoma.
    Matsumoto K; Imai R; Kamada T; Maruyama K; Tsuji H; Tsujii H; Shioyama Y; Honda H; Isu K;
    Cancer; 2013 Oct; 119(19):3496-503. PubMed ID: 23939877
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
    Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Definitive carbon ion radiotherapy for tracheobronchial adenoid cystic carcinoma: a preliminary report.
    Chen J; Mao J; Ma N; Wu KL; Lu J; Jiang GL
    BMC Cancer; 2021 Jun; 21(1):734. PubMed ID: 34174854
    [TBL] [Abstract][Full Text] [Related]  

  • 73. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
    Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
    Yu HH; Song DY; Tsai YY; Thompson T; Frassica DA; DeWeese TL
    Urology; 2007 Jul; 70(1):111-6. PubMed ID: 17656219
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Definitive carbon-ion radiotherapy for locally advanced parotid gland carcinomas.
    Koto M; Hasegawa A; Takagi R; Ikawa H; Naganawa K; Mizoe JE; Jingu K; Tsujii H; Tsuji H; Kamada T; Okamoto Y;
    Head Neck; 2017 Apr; 39(4):724-729. PubMed ID: 28006083
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Carbon ion radiotherapy for sacral chordoma: A retrospective nationwide multicentre study in Japan.
    Demizu Y; Imai R; Kiyohara H; Matsunobu A; Okamoto M; Okimoto T; Tsuji H; Ohno T; Shioyama Y; Nemoto K; Nakano T; Kamada T;
    Radiother Oncol; 2021 Jan; 154():1-5. PubMed ID: 32941958
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Moderate hypofractionated external beam radiotherapy alone for intermediate risk prostate cancer: long term outcomes.
    Faria SL; Neto OB; Cury F; Shenouda G; Russel R; Souhami L
    Can J Urol; 2016 Apr; 23(2):8209-14. PubMed ID: 27085825
    [TBL] [Abstract][Full Text] [Related]  

  • 78. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
    Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
    Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
    [TBL] [Abstract][Full Text] [Related]  

  • 79. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience.
    Sylvester JE; Grimm PD; Blasko JC; Millar J; Orio PF; Skoglund S; Galbreath RW; Merrick G
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):57-64. PubMed ID: 17084544
    [TBL] [Abstract][Full Text] [Related]  

  • 80. External-beam radiotherapy for localized or locally advanced prostate cancer in Japan: a multi-institutional outcome analysis.
    Nakamura K; Mizowaki T; Imada H; Karasawa K; Uno T; Onishi H; Nihei K; Sasaki S; Ogura M; Akimoto T
    Jpn J Clin Oncol; 2008 Mar; 38(3):200-4. PubMed ID: 18304950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.